FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

ashington, D.C. 20549	
-----------------------	--

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Bray June					2. Issuer Name and Ticker or Trading Symbol BioXcel Therapeutics, Inc. [BTAI]						(Ch	elationship of the contract of	able) r	Person	10% Ow	ner	
(Last) (First) (Middle) C/O BIOXCEL THERAPEUTICS, INC.					3. Date of Earliest Transaction (Month/Day/Year) 06/11/2021							Officer below)	(give title		Other (specification)	pecify	
555 LONG WHARF DRIVE					4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable					
(Street)	AVEN C	Γ	06511								Line	X Form fi	led by One led by More	•	Ü		
(City)	(S	tate)	(Zip)														
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																
Date				Transactior ate Ionth/Day/Yo	Execution Date,			Code (Inst	Transaction Disposed Of (D) (Instr. 3, 4) Code (Instr. 5)			5. Amour Securitie Beneficia Owned F Reported	s ally ollowing	6. Owne Form: D (D) or In (I) (Instr.	Direct Condirect E	7. Nature of Indirect Beneficial Ownership	
						Code V	Amount	(A) or (D)	Price	Transact (Instr. 3 a	ion(s)		("	Instr. 4)			
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	rsion Date (Month/Day/Year) Execution if any (Month/Day	3A. Deemed Execution Date if any (Month/Day/Yea	Date, Transaction Code (Ins				6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	y Di or (I)	0. wnership orm: irect (D) r Indirect) (Instr. 4)	Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares						
Stock Option (Right to Buy)	\$37.86	06/11/2021		A		25,000		(1)	06/11/2031	Common Stock	25,000	\$0	25,000		D		

Explanation of Responses:

1. The option will vest in full and become exercisable in three substantially equal annual installments following the date of grant, such that the option shall be fully vested on the third anniversary of the date of grant, subject to the Reporting Person's continued service through such vesting date.

> /s/ Richard I. Steinhart, Attorney-in-Fact for June Bray

06/15/2021

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.